secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcturus Therapeutics Holdings Inc. (ARCT)
CIK:        0001768224
Form:       8-K
Filed at:   2022-11-02T23:59:59+00:00
Accession:  0001193805-22-001470
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcturus signs $200M upfront collaboration with CSL Seqirus for self-amplifying mRNA vaccines
--------------------------------------------------------------------------------

- Arcturus receives $200M upfront; eligible for >$1.3B development and >$3B commercial milestones.
- 40% net profit share on COVID-19 vaccines; up to double-digit royalties on flu, pandemic, and 3 other respiratory vaccines.
- Collaboration covers self-amplifying mRNA vaccines for COVID-19, influenza, pandemic preparedness, and three other respiratory diseases.
- CSL Seqirus leads development and commercialization; Arcturus provides STARR technology and LUNAR delivery platform.
- Transaction subject to HSR Act waiting period; J.P. Morgan advised Arcturus.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1768224/000119380522001470/0001193805-22-001470-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1768224/000119380522001470/e617985_8k-arct.htm
  HTML page:      https://secwatch.observer/filing/0001193805-22-001470

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer